

Special Issue

COVID-19 and Pregnancy: Prevention and Control Strategies for Coronavirus in Women

Message from the Guest Editor

The novel severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) began in Wuhan, China in December 2019. As of 17 March 2020, 153 countries had reported cases of infection caused by this virus, with Italy becoming the new epicentre. COVID-19 is a global public health emergency and could cause devastating health issues during pregnancy. Interim COVID-19 guidelines for the effective counselling and education of pregnant women are currently available from the Center for Disease Control and Prevention (CDC) and the World Health Organization (WHO). Recommendations which were published following the COVID epidemic in Wuhan are also available from Chinese experts. December 2019. At the same time, the fact that results from studies concerning COVID-19 infection in pregnant and lactating women are being published so quickly may be a limitation of any review of the literature. More original studies regarding infected pregnant women are needed to establish totally evidence-based protocols of care for these patients.

Guest Editor

Dr. Gianluca Straface

Division of Perinatal Medicine, Abano Terme, Italy

Deadline for manuscript submissions

closed (31 January 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/140320

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).